Search Results 711-720 of 18336 for alopecia

1. Trial of 225Ac-DOTATATE (RYZ101) Alone and with Pembrolizumab in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs (TRACY-1) - Mayo Clinic

   * Any toxicities from prior treatments that have not recovered to CTCAE Grade ≤1, except for alopecia. * Significant cardiovascular disease * Known brain ...

2. Mayo Clinic

   Fuel groundbreaking medical research! ... Your donation powers the future of medicine and helps save lives. Give Today.

3. Highlights of a healthy living cooking demonstration - Mayo Clinic

   Appointments at Mayo Clinic. Mayo Clinic offers appointments in Arizona, Florida and Minnesota and at Mayo Clinic Health System locations.

4. A Trial of ZL-1201 in Subjects with Advanced Cancer - Mayo Clinic

   Recovery to Grade 0-1, from adverse events related to prior anticancer therapy except alopecia, ≤ Grade 2 sensory neuropathy, lymphopenia, and ...

5. A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies - Mayo Clinic

   0) ≤ Grade 1, or to the levels dictated in the eligibility criteria with the exception of alopecia. Patient with history of confirmed progressive ...

6. Phase III Study Of Datopotamab Deruxtecan Versus Docetaxel In Previously Treated TROP2-positive Advanced Non-squamous NSCLC Without AGA - Mayo Clinic

   Participation eligibility · Persistent toxicities caused by previous anti-cancer therapy, excluding alopecia, not yet improved to Grade ≤ 1 or baseline. · Has ...

7. Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL - Mayo Clinic

   ... alopecia) due to therapy administered prior to the initiation of study drug dosing. Nursing or pregnant. Known allergy or hypersensitivity to any of the ...

8. Abiraterone/Prednisone, Olaparib, Or Abiraterone/Prednisone + Olaparib In Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects - Mayo Clinic

   Persistent toxicities (≥CTCAE Grade 2), with the exception of alopecia, caused by previous cancer therapy. Resting ECG with QTc > 470msec on 2 or more time ...

9. Study to Evaluate the Safety and Effectiveness of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Relapsed/Refractory Large B-cell Lymphoma - Mayo Clinic

   Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1 (except for clinically non-significant toxicities, such as alopecia). Age 18 ...

10. A Phase 1-2 Multi-Center Study Evaluating Axicabtagene Ciloleucel in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) - Mayo Clinic

    Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1 (except for clinically non-significant toxicities such as alopecia). Age 18 years ...